WASHINGTON--(BUSINESS WIRE)--A white paper released today by Alex Brill, a former House Ways and Means Committee chief economist and senior advisor and currently a research fellow at the American Enterprise Institute, found that a sufficient data exclusivity period to grant brand biologics manufacturers before biogenerics can come to market is seven years, rather than the 14 years currently supported by the Biotechnology Industry Organization (BIO).
